[video+transcript]How Geron's Horrible Year Is a Great Reminder to Investors

Disappointing news that Johnson & Johnson (NYSE: JNJ) decided to walk away from a collaboration with Geron Corp. (NASDAQ: GERN) on the latter's only drug, imetelstat, has sent Geron's shares reeling and cast doubt on its future.